These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

831 related items for PubMed ID: 25376448

  • 1. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study.
    Mrowietz U, Chouela EN, Mallbris L, Stefanidis D, Marino V, Pedersen R, Boggs RL.
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1114-20. PubMed ID: 25376448
    [Abstract] [Full Text] [Related]

  • 2. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial.
    Thaçi D, Galimberti R, Amaya-Guerra M, Rosenbach T, Robertson D, Pedersen R, Yang S, Kuligowski M, Boggs R.
    J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):900-6. PubMed ID: 23848989
    [Abstract] [Full Text] [Related]

  • 3. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.
    Dermatology; 2009 Jul; 219(3):239-49. PubMed ID: 19752505
    [Abstract] [Full Text] [Related]

  • 4. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
    Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, Boggs R, Zbrozek AS.
    J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
    [Abstract] [Full Text] [Related]

  • 5. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
    Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, Molta CT, Boggs R.
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):896-904. PubMed ID: 19453794
    [Abstract] [Full Text] [Related]

  • 6. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
    Daudén E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, Pedersen R, Estojak J, Boggs R.
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1374-82. PubMed ID: 19563497
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis.
    Dougados M, Tsai WC, Saaibi DL, Bonin R, Bukowski J, Pedersen R, Vlahos B, Kotak S.
    J Rheumatol; 2015 Oct; 42(10):1835-41. PubMed ID: 26276968
    [Abstract] [Full Text] [Related]

  • 8. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [Abstract] [Full Text] [Related]

  • 9. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.
    Ortonne JP, Paul C, Berardesca E, Marino V, Gallo G, Brault Y, Germain JM.
    Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207
    [Abstract] [Full Text] [Related]

  • 10. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE.
    J Drugs Dermatol; 2004 May; 3(1):27-38. PubMed ID: 14964744
    [Abstract] [Full Text] [Related]

  • 11. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.
    Griffiths CE, Sterry W, Brock F, Dilleen M, Stefanidis D, Germain JM, Mallbris L.
    Br J Dermatol; 2015 Jan; 172(1):230-8. PubMed ID: 24861696
    [Abstract] [Full Text] [Related]

  • 12. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 13. Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial.
    Zhu B, Edson-Heredia E, Guo J, Maeda-Chubachi T, Shen W, Kimball AB.
    Br J Dermatol; 2014 Nov; 171(5):1215-9. PubMed ID: 24749812
    [Abstract] [Full Text] [Related]

  • 14. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial.
    Kemeny L, Amaya M, Cetkovska P, Rajatanavin N, Lee WR, Szumski A, Marshall L, Mahgoub EY, Aldinç E.
    BMC Dermatol; 2015 May 21; 15():9. PubMed ID: 25994179
    [Abstract] [Full Text] [Related]

  • 15. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity.
    Korman NJ, Zhao Y, Pike J, Roberts J, Sullivan E.
    Dermatol Online J; 2015 Oct 16; 21(10):. PubMed ID: 26632793
    [Abstract] [Full Text] [Related]

  • 16. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP, Shear N, Shumack S, Henninger E, CLEAR Multinational Study Group.
    BMC Dermatol; 2005 Dec 16; 5():13. PubMed ID: 16359548
    [Abstract] [Full Text] [Related]

  • 17. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.
    Health Qual Life Outcomes; 2006 Sep 27; 4():71. PubMed ID: 17005043
    [Abstract] [Full Text] [Related]

  • 18. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB.
    JAMA Dermatol; 2020 Dec 01; 156(12):1344-1353. PubMed ID: 33052382
    [Abstract] [Full Text] [Related]

  • 19. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA.
    Korman NJ, Zhao Y, Pike J, Roberts J.
    Clin Exp Dermatol; 2016 Jul 01; 41(5):514-21. PubMed ID: 27061102
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.
    Arch Dermatol; 2005 Jan 01; 141(1):31-8. PubMed ID: 15655139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.